CliffBio
small molecule

SLYND

DROSPIRENONE

Loss of exclusivityJune 2031latest FDA-listed patent expiry
CompanyExeltis USA, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameSLYND
Active ingredientDROSPIRENONE
Strength4MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2019
Marketing statusRX

Listed patents

PatentExpiresType
10179140June 2031use U-2553
12090231June 2031use U-2553
9603860June 2031use U-2553
10603281June 2031use U-2553
11413249June 2031use U-2553
10849857June 2031product
11951213June 2031use U-2553
11478487June 2031product
11504334June 2031product
11123299June 2031product
10987364June 2031product
11291632June 2031product
11291633June 2031product
12280151June 2031product
11351122June 2031product

More from Exeltis USA, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SLYND patent cliff — loss of exclusivity June 2031 | CliffBio